Small Molecules in Oncology
Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small m...
Corporate Author: | |
---|---|
Other Authors: | |
Format: | Electronic eBook |
Language: | English |
Published: |
Berlin, Heidelberg :
Springer Berlin Heidelberg,
2010.
|
Series: | Recent Results in Cancer Research,
184 |
Subjects: | |
Online Access: | Full Text via HEAL-Link |
Table of Contents:
- Protein kinase inhibitors
- Imatinib Mesylate
- Erlotinib
- Axitinib (AG-013736)
- Lapatinib
- Sorafenib
- Sunitinib
- Dasatinib
- Nilotinib
- Bosutinib
- Epigenetic modifiers
- Decitabine
- 5-Azacytidine/Azacitidine
- Cell cycle inhibitors
- Bortezomib
- Temsirolimus
- Danusertib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor
- BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1)
- Other novel agents
- Imetelstat (GRN163L) - Telomerase-Based Cancer Therapy
- GDC-0449 - Targeting the Hedgehog Signaling Pathway.